Sigyn Therapeutics (SIGY) Current Assets (2016 - 2025)
Sigyn Therapeutics (SIGY) posted Current Assets of $85571.0 for Q3 2025, up 4764.75% sequentially from $1759.0 in Q2 2025, and down 68.2% YoY from $269108.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Current Assets (2016 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Current Assets for 10 years, with the latest figure at $85571.0 in Q3 2025.
- Quarterly Current Assets fell 68.2% year-over-year to $85571.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $85571.0 (down 68.2% YoY) and the FY2024 annual result came in at $21244.0, down 82.01% from the prior year.
- Current Assets improved to $85571.0 in Q3 2025 per SIGY's latest filing, from $1759.0 in the prior quarter.
- Over five years, Current Assets peaked at $1.7 million in Q2 2021 and troughed at $1759.0 in Q2 2025.
- A 5-year average of $301854.3 and a median of $134428.0 in 2024 frame the typical range for Current Assets.
- The sharpest annual moves came in 2023 and 2025: Current Assets soared 187.19% in 2023, then slumped 98.8% in 2025.
- Over 5 years, Current Assets stood at $393031.0 in 2021, then plunged by 82.11% to $70298.0 in 2022, then soared by 67.95% to $118063.0 in 2023, then slumped by 82.01% to $21244.0 in 2024, then jumped by 302.8% to $85571.0 in 2025.
- According to Business Quant data, Current Assets over the past three periods registered $85571.0, $1759.0, and $68095.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 85,571.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 85,571.00 |
| Jun 30, 2025 | 1,759.00 |
| Mar 31, 2025 | 68,095.00 |
| Dec 31, 2024 | 21,244.00 |
| Sep 30, 2024 | 269,108.00 |
| Jun 30, 2024 | 146,376.00 |
| Mar 31, 2024 | 134,428.00 |
| Dec 31, 2023 | 118,063.00 |
| Sep 30, 2023 | 168,871.00 |
| Jun 30, 2023 | 128,795.00 |
| Mar 31, 2023 | 412,488.00 |
| Dec 31, 2022 | 70,298.00 |
| Sep 30, 2022 | 85,377.00 |
| Jun 30, 2022 | 104,997.00 |
| Mar 31, 2022 | 143,630.00 |
| Dec 31, 2021 | 393,031.00 |
| Sep 30, 2021 | 1.12 Mn |
| Jun 30, 2021 | 1.67 Mn |
| Mar 31, 2021 | 593,154.00 |
| Dec 31, 2020 | 670,449.00 |